Subtype
Malignant Male Reproductive System Neoplasm
CI-CAN-00003180Explore in graph →
1,454 active trials27 approved drugs58 evidence items
- NCIt
- C8561
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003180Explore in graph →
Clinical trials
6,230 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (762)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02137746 | Study to Allow for Second Treatment Cycle of DCVAC in Patients With Localized Prostate Cancer | completed | Phase 2 | 24 | SOTIO a.s.INDUSTRY | 1 | May 24, 2017 | clinicaltrials |
| NCT00715078 | To Evaluate Sipuleucel-T Manufactured With Different Concentrations of (PA2024) Antigen | completed | Phase 2 | 122 | DendreonINDUSTRY | 1 | May 23, 2017 | clinicaltrials |
| NCT00795769 |
| Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant |
| completed |
| Phase 2 |
| 49 |
| Fred Hutchinson Cancer CenterOTHER |
| 1 |
| May 23, 2017 |
| clinicaltrials |
| NCT00901342 | Open Label Study of Sipuleucel-T in Metastatic Prostate Cancer | completed | Phase 2 | 104 | DendreonINDUSTRY | 1 | May 23, 2017 | clinicaltrials |
| NCT01385293 | BKM120 in Metastatic Castration-resistant Prostate Cancer | terminated | Phase 2 | 30 | Andrew J. Armstrong, MDOTHER | 1 | May 19, 2017 | clinicaltrials |
| NCT01427881 | Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies | completed | Phase 2 | 43 | Fred Hutchinson Cancer CenterOTHER | 1 | May 19, 2017 | clinicaltrials |
| NCT00049504 | Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer | completed | Phase 2 | 53 | Fred Hutchinson Cancer CenterOTHER | 1 | May 17, 2017 | clinicaltrials |
| NCT00170157 | Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer | completed | Phase 2 | 112 | Mayo ClinicOTHER | 1 | May 15, 2017 | clinicaltrials |
| NCT01215032 | Metformin in Castration-Resistant Prostate Cancer | terminated | Phase 2 | 21 | Massachusetts General HospitalOTHER | 1 | May 15, 2017 | clinicaltrials |
| NCT01735396 | Abiraterone Acetate Trial in African American Prostate Cancer Patients | terminated | Phase 2 | 11 | Icahn School of Medicine at Mount SinaiOTHER | 1 | May 12, 2017 | clinicaltrials |
| NCT02022371 | Prostate Cancer Genomic Heterogeneity(PROGENY) | completed | Phase 1 / Phase 2 | 50 | University College London HospitalsOTHER | 1 | May 10, 2017 | clinicaltrials |
| NCT01828476 | Navitoclax and Abiraterone Acetate With or Without Hydroxychloroquine in Treating Patients With Progressive Metastatic Castrate Refractory Prostate Cancer | terminated | Phase 2 | 13 | Rutgers, The State University of New JerseyOTHER | 1 | May 4, 2017 | clinicaltrials |
| NCT00182741 | Calcitriol, Mitoxantrone, and Prednisone in Treating Patients With Metastatic Prostate Cancer | completed | Phase 2 | 19 | OHSU Knight Cancer InstituteOTHER | 1 | May 3, 2017 | clinicaltrials |
| NCT03137186 | Repurposing Metformin as Anticancer Drug: in Advanced Prostate Cancer(Mansmed) | unknown | Phase 2 | 120 | Mansoura UniversityOTHER | 1 | May 2, 2017 | clinicaltrials |
| NCT00003781 | Docetaxel in Treating Patients With Stage IV Prostate Cancer | completed | Phase 2 | 25 | OHSU Knight Cancer InstituteOTHER | 1 | Apr 28, 2017 | clinicaltrials |
| NCT00004043 | Calcitriol in Treating Patients With a Rising PSA Level Following Treatment for Prostate Cancer | completed | Phase 2 | 25 | OHSU Knight Cancer InstituteOTHER | 1 | Apr 28, 2017 | clinicaltrials |
| NCT00017563 | Combination Chemotherapy Followed by Surgery in Treating Patients With Localized Prostate Cancer | completed | Phase 2 | 57 | OHSU Knight Cancer InstituteOTHER | 1 | Apr 28, 2017 | clinicaltrials |
| NCT00017576 | Calcitriol and Carboplatin in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy | completed | Phase 2 | 19 | OHSU Knight Cancer InstituteOTHER | 1 | Apr 28, 2017 | clinicaltrials |
| NCT00459810 | Paclitaxel Poliglumex and Estradiol in Treating Patients With Stage IV Prostate Cancer | terminated | Phase 2 | 21 | OHSU Knight Cancer InstituteOTHER | 1 | Apr 28, 2017 | clinicaltrials |
| NCT00482274 | Docetaxel in Treating Patients With Relapsed Prostate Cancer | terminated | Phase 2 | 3 | OHSU Knight Cancer InstituteOTHER | 1 | Apr 28, 2017 | clinicaltrials |
| NCT01228084 | Sulforaphane in Treating Patients With Recurrent Prostate Cancer | completed | Phase 2 | 20 | OHSU Knight Cancer InstituteOTHER | 1 | Apr 28, 2017 | clinicaltrials |
| NCT02840162 | Pre-Prostatectomy Celecoxib or Placebo | terminated | Phase 2 | 34 | OHSU Knight Cancer InstituteOTHER | 1 | Apr 28, 2017 | clinicaltrials |
| NCT02212197 | Phase II Study of Subcutaneous Injection Depot of Leuprolide Acetate in Patient With Prostate Cancer | completed | Phase 2 | 51 | Camurus ABINDUSTRY | 2 | Apr 25, 2017 | clinicaltrials |
| NCT03124615 | Effect of Enzalutamide Dose Reduction on Fatigue, Cognition, and Drug Trough Levels in Patients With Prostate Cancer(EFFECT) | unknown | Phase 2 | 47 | Macquarie University, AustraliaOTHER | 1 | Apr 24, 2017 | clinicaltrials |
| NCT00669656 | Herbal Therapy for Treatment of Recurrent Prostate Cancer | completed | Phase 2 | 43 | University of Southern CaliforniaOTHER | 1 | Apr 20, 2017 | clinicaltrials |
| NCT02016040 | Focal Therapy Using HIFU for Localised Prostate Cancer | unknown | Phase 2 / Phase 3 | 25 | Jewish General HospitalOTHER | 1 | Apr 19, 2017 | clinicaltrials |
| NCT00118092 | 17-AAG in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy | completed | Phase 2 | 17 | National Cancer Institute (NCI)NIH | 1 | Apr 18, 2017 | clinicaltrials |
| NCT02135445 | Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer | completed | Phase 2 | 103 | Millennium Pharmaceuticals, Inc.INDUSTRY | 2 | Apr 13, 2017 | clinicaltrials |
| NCT00574769 | Safety Study & Effectiveness of Docetaxel With RAD001 and Bevacizumab in Men With Advanced Prostate Cancer | completed | Phase 1 / Phase 2 | 27 | University of Southern CaliforniaOTHER | 1 | Apr 11, 2017 | clinicaltrials |
| NCT01450683 | Study of Itraconazole in Castrate-resistant Prostate Cancer (CRPC) Post-chemotherapy | terminated | Phase 2 | 4 | Stanford UniversityOTHER | 1 | Apr 11, 2017 | clinicaltrials |
| NCT02440308 | 68Ga-DOTA-Bombesin PET/MRI in Imaging Patients With Prostate Cancer | completed | Phase 2 | 10 | Stanford UniversityOTHER | 1 | Apr 11, 2017 | clinicaltrials |
| NCT00895310 | Use of Low Dose Ketoconazole in Prostate Cancer That Does Not Respond to Hormone Therapy and Prior Chemotherapy | completed | Phase 2 | 30 | University of California, DavisOTHER | 1 | Mar 30, 2017 | clinicaltrials |
| NCT00769795 | Study of Effectiveness of IMC-A12 Antibody Combined With Hormone Therapy Prior to Surgery to Treat Prostate Cancer | completed | Phase 2 | 29 | University of WashingtonOTHER | 1 | Mar 29, 2017 | clinicaltrials |
| NCT01317641 | Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 136 | Orion Corporation, Orion PharmaINDUSTRY | 6 | Mar 29, 2017 | clinicaltrials |
| NCT01695044 | A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC) | completed | Phase 2 | 119 | Progenics Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 24, 2017 | clinicaltrials |
| NCT02020135 | An Open-label Extension Study of PSMA ADC 2301 in mCRPC | completed | Phase 2 | 9 | Progenics Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 24, 2017 | clinicaltrials |
| NCT02656615 | Abiraterone-Rechallenge Study for CRPC Patients(ABI-RE) | terminated | Phase 2 | 4 | Aurelius OmlinOTHER | 1 | Mar 24, 2017 | clinicaltrials |
| NCT02483884 | PET/CT Imaging Study of the Safety and Diagnostic Performance of [68Ga]RM2 in Patients With Primary Prostate Cancer | terminated | Phase 1 / Phase 2 | 30 | Lantheus Biosciences Ltd.INDUSTRY | 2 | Mar 22, 2017 | clinicaltrials |
| NCT03085966 | Autologous Immune Cell Therapy in Combination With LHRH-a in Patients With mCRPC | unknown | Phase 1 / Phase 2 | 30 | Shanghai AbelZeta Ltd.INDUSTRY | 1 | Mar 21, 2017 | clinicaltrials |
| NCT00957905 | Alvocidib and Oxaliplatin With or Without Fluorouracil and Leucovorin Calcium in Treating Patients With Relapsed or Refractory Germ Cell Tumors | completed | Phase 2 | 36 | National Cancer Institute (NCI)NIH | 1 | Mar 10, 2017 | clinicaltrials |
| NCT01620515 | Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer | completed | Phase 2 | 141 | Nymox CorporationINDUSTRY | 1 | Mar 10, 2017 | clinicaltrials |
| NCT00138918 | Study of OGX-011 Given Prior to Radical Prostatectomy in Patients With Localized Prostate Cancer | completed | Phase 2 | 20 | University of British ColumbiaOTHER | 1 | Mar 3, 2017 | clinicaltrials |
| NCT01087580 | Docetaxel + Prednisone With or Without Radiation for Castrate Resistant Prostate Cancer | withdrawn | Phase 2 | 0 | Northwestern UniversityOTHER | 1 | Mar 3, 2017 | clinicaltrials |
| NCT00049309 | Low-Fat Diet and/or Flaxseed in Preventing Prostate Cancer | completed | Phase 2 | 161 | Duke UniversityOTHER | 1 | Feb 23, 2017 | clinicaltrials |
| NCT00058084 | Ixabepilone Compared With Mitoxantrone and Prednisone in Treating Patients With Refractory Metastatic Prostate Cancer | completed | Phase 2 | 80 | National Cancer Institute (NCI)NIH | 1 | Feb 23, 2017 | clinicaltrials |
| NCT00303875 | Exercise and Dietary Counseling in Improving Physical Activity, Nutrition, and Quality of Life in Older Long-Term Cancer Survivors Who Are Overweight | completed | Phase 2 | 641 | Duke UniversityOTHER | 1 | Feb 23, 2017 | clinicaltrials |
| NCT01429064 | Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001 | completed | Phase 2 | 76 | Orion Corporation, Orion PharmaINDUSTRY | 6 | Feb 20, 2017 | clinicaltrials |
| NCT01817738 | Trial of RNActive®-Derived Prostate Cancer Vaccine in Metastatic Castrate-refractory Prostate Cancer | terminated | Phase 1 / Phase 2 | 197 | CureVacINDUSTRY | 8 | Feb 17, 2017 | clinicaltrials |
| NCT01667536 | A Phase 2 Study With MIP-1404 in Men With High-Risk PC Scheduled for RP and EPLND Compared to Histopathology | completed | Phase 2 | 105 | Molecular Insight Pharmaceuticals, Inc.INDUSTRY | 8 | Feb 7, 2017 | clinicaltrials |
| NCT00879619 | Taxotere/Prednisone Plus Sunitinib in Chemotherapy-Naïve, Hormone Refractory Prostate Cancer Patients | terminated | Phase 1 / Phase 2 | 4 | John P. FruehaufOTHER | 1 | Feb 1, 2017 | clinicaltrials |
Data updated 24 days agoSource updated May 24, 2017source: clinicaltrials